Sutro Biopharma (STRO)
(Delayed Data from NSDQ)
$4.34 USD
+0.11 (2.60%)
Updated May 14, 2024 04:00 PM ET
After-Market: $4.33 -0.01 (-0.23%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Price, Consensus and EPS Surprise
STRO 4.34 +0.11(2.60%)
Will STRO be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for STRO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for STRO
Spruce Biosciences, Inc. (SPRB) Reports Q1 Loss, Tops Revenue Estimates
Analysts Estimate Sutro Biopharma, Inc. (STRO) to Report a Decline in Earnings: What to Look Out for
STRO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Novavax (NVAX) Reports Q1 Loss, Lags Revenue Estimates
Atara Biotherapeutics (ATRA) Reports Q1 Loss, Tops Revenue Estimates
AnaptysBio (ANAB) Soars 14.3%: Is Further Upside Left in the Stock?
Other News for STRO
Analysts Offer Insights on Healthcare Companies: Sutro Biopharma (STRO), Edgewise Therapeutics (EWTX) and Forte Biosciences (FBRX)
Piper Sandler Remains a Buy on Sutro Biopharma (STRO)
Buy Rating on Sutro Biopharma: Promising Trials and Market Expansion Potential for Luvelta
Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones
STRO Stock Earnings: Sutro Biopharma Misses EPS, Beats Revenue for Q1 2024